BIO-RAD LABORATORIES, INC. acquires Stilla Technologies
Snapshot
BIO-RAD LABORATORIES, INC. acquired Stilla Technologies for approximately $257.7 million purchase consideration ($166.5M cash to sellers, $47.6M cash paid to debtors on Stilla's behalf, $15.0M to escrow, plus $28.6M fair value of contingent consideration of up to $50.0M) in June 2025. The transaction was structured as all cash plus contingent consideration. Stilla Technologies is a France-based Life Science business.
- Acquirer
- BIO-RAD LABORATORIES, INC.
- Target
- Stilla Technologies
- Value
- approximately $257.7 million purchase consideration ($166.5M cash to sellers, $47.6M cash paid to debtors on Stilla's behalf, $15.0M to escrow, plus $28.6M fair value of contingent consideration of up to $50.0M)
- Date
- June 2025
- Type
- full acquisition
- Status
- ready
The deal at a glance
About this deal
BIO-RAD LABORATORIES, INC. acquired Stilla Technologies for approximately $257.7 million purchase consideration ($166.5M cash to sellers, $47.6M cash paid to debtors on Stilla's behalf, $15.0M to escrow, plus $28.6M fair value of contingent consideration of up to $50.0M), a transaction completed in June 2025, structured as all cash plus contingent consideration.
Stilla Technologies operates in Life Science, is based in France. Stilla Technologies is a commercial-stage life science company that develops and markets next-generation droplet digital PCR (Polymerase Chain Reaction) systems supporting a broad range of genetic and molecular testing applications.
The strategic rationale for the transaction was to strengthen our offering in droplet digital PCR and facilitate entry into new molecular testing markets.
Commercial-stage, next-generation droplet digital PCR technology adjacent to Bio-Rad's existing ddPCR franchise. Strengthens Bio-Rad's droplet digital PCR offering and supports entry into new molecular testing markets. Life Science segment
No advisory firms have been disclosed for this transaction.